Drugs / INO-4700
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04588428 | Jun 2021 → Jan 2023 | Middle East respiratory syndrome | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Inovio Pharmaceuticals | Results INOVIO Provides an Update on Lassa Fever and MERS Programs inovio.com ↗
Although INO-4500 and INO-4700 were well-tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development. |
| 2020-04-28 | Inovio Pharmaceuticals | Results INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference inovio.com ↗
Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg of INO-4700, a DNA vaccine that targets the MERS-CoV Spike (S) glycoprotein, delivered with intradermal CELLECTRA® device. |
| 2019-07-25 | Inovio Pharmaceuticals | Results Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases inovio.com ↗
Subjects vaccinated with INO-4700 displayed robust levels of MERS antigen-specific antibody and T cell responses at week 14 (two weeks post-third dose). |
| 2018-06-27 | Inovio Pharmaceuticals | Results Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study inovio.com ↗
Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science Inc. (KSE:011000), showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Inovio Pharmaceuticals | INOVIO Provides an Update on Lassa Fever and MERS Programs inovio.com ↗ |
| 2020-04-28 | Inovio Pharmaceuticals | INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference inovio.com ↗ |
| 2019-07-25 | Inovio Pharmaceuticals | Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases inovio.com ↗ |
| 2018-06-27 | Inovio Pharmaceuticals | Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-4700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04588428 ↗ |
| Modality | Vaccine | “a DNA vaccine against the MERS-CoV spike glycoprotein” PMID 41322416 ↗ Nov 2025 |
| Route | Other | “Participants received INO-4700 or placebo intradermally” PMID 41322416 ↗ Nov 2025 |